Abstract

Renal handling of magnesium (Mg) is an adaptive mechanism, but it's affected when renal function declines. In moderate chronic kidney disease (CKD), loss of glomerular filtration is compensated by higher fractional excretion of Mg. In more advanced CKD however, (creatinine clearance <30 mL/min), overt hypermagnesemia develops frequently. Various studies show that increased serum Mg (sMg) lowers PTH, others do not prove the suggestion. Although the exact role of Mg in bone metabolism is unclear, it may have both positive and negative effects. The aim of this study is to investigate the impact of sMg on bone mineral metabolism in CKD patients with or without diabetes. 62 CKD patients (not receiving dialysis) were divided into two groups: 1st group (32 CKD diabetic patients); 2nd group (30 CKD patients without diabetes). Biochemical determinations were made, and the estimated glomerular filtration rate (GFR) was measured. Bone mineral density (BMD) was measured by dual-energy X-ray absorptiometry. sMg was inversely correlated with sCa (P<0.02) and with parathyroid hormone (sPTH) (P<0.05), with alkaline phosphatase (AP) (P<0.02), and with phosphate (P) (P<0.01) in 1st group (diabetic). The CKD diabetic patients had lower serum albumin (ALB) and a higher hypomagnesemia and osteoporosis than the nondiabetic patients. sMg inversely correlated with e-GFR in the CKD patients in both groups. sMg showed higher correlation with 25-hydroxyvitamin D in 2nd non-diabetic group (P<0.01); diabetic patients with higher sMg had a lower iPTH. The lower sMg subgroup showed a higher incidence of osteoporosis than the moderate and higher sMg subgroups did. In conclusion, low sMg may impact iPTH and enlarge osteoporosis in CKD patients, particularly with diabetes.

Introduction

Renal excretion of Mg is so adaptable, that impairment of renal function was recognized as an important reason for development of hypermagnesemia [1-3]. In moderate CKD, increase in fractional Mg excretion compensates impaired renal function, and sMg remains normal [1,3,4]. Interestingly, there seem to be differences in Mg homeostasis of diabetics and non-diabetics. When patients with and without diabetes were investigated (creatinine clearance ranging from 115 to >30 mL/min/1.73 m²), a significant inverse correlation was found between creatinine clearance and serum magnesium in non-diabetics, but not in diabetics. As renal function further deteriorates to CKD Stages 4 and 5, the quantitative excretion of Mg tends to decrease and cannot be compensated any longer by an increased fractional excretion [5,6]. Osteoporosis is a skeletal disorder with disruption of bone architecture that leads to decreased bone mass, strength and increased fracture risk. Many factors are associated with osteoporosis: nutritional, hormonal, low calcium (Ca), Vitamin D deficiency. CKD causes abnormality of bone mineral metabolism and results in some special kinds of bone disease [5,7-9]. Mg is also a regulator of bone homeostasis, influencingPTH secretion, Vitamin D metabolism and bone structure per se [7,10,11].

In the present study, sMg levels, bone mineral metabolism parameters, bone mineral density, and renal function indicators were measured. The objective of this study was to evaluate the impacts of serum Mg levels on PTH and bone mineral metabolism among CKD patients with or without diabetes.

Material and methods

This study involved 62 stage 3–5 CKD patients, not receiving dialysis who were divided into two groups: 32 CKD with diabetes and 30 CKD without diabetes. Patients were residents in Sofia and Stara Zagora and were diagnosed with CKD. All patients were without a history of severe symptomatic ischemic heart disease, heart failure, liver disease, malignancy, and hypoparathyroidism.

The study protocol was approved by the Local Medical Ethic Committee and informed consent was obtained from each participant.

Blood samples were collected after an overnight fasting for the determinations of serum Mg, Ca, P, intact PTH (iPTH), alkaline phosphatase (ALP), 25-hydroxyvitamin D (25(OH)D). (For patients with stages 3, 4, and 5 CKD, PTH should be maintained in the range

*Correspondence to: Diana Yonova, Nephrology Department, Medical University Hospital "Lozenetz", Sofia, Bulgaria, E-mail: yonovad@abv.bg

Key words: magnesium (Mg), chronic kidney disease (CKD), diabetic patients, bone mineral metabolism (BMM)

Received: December 16, 2019; Accepted: January 03, 2020; Published: January 06, 2020
The impact of Magnesium (Mg) on mineral metabolism in diabetic or non-diabetic patients with chronic kidney diseases (CKD)

Table 1. Characteristics of the 62 non-dialysis CKD patients with or without diabetes

| Variables          | Total (62) | Diabetes (32) | Non-diabetes (30) | P<  
|--------------------|------------|---------------|-------------------|-------
| Age (y)            | 64.0 (63.0–75.0) | 69.2 (57.0–76.6) | 65.0 (52.8–76.6) | NS    
| GFR (mL/min)       | 19.5 (11.5–28.3) | 14.7 (9.2–28.7)  | 21.4 (11.0–23.6) | 0.01  
| CKD Stages         |             |               |                   |       
| Stage 3            | n=16       | n=9           | n=6               |       
| Stage 4            | n=20       | n=27          | n=14              |       
| Stage 5            | n=26       | n=16          | n=10              |       
| Alb (g/dL)         | 3.9 ± 0.5  | 3.6 ± 0.4     | 3.9 ± 0.5         | 0.05  
| sMg (mmol/L)       |             |               |                   |       
| low sMg (<0.6 mmol/L) | 6 (0.4 ± 0.13) | 6 (0.4 ± 0.13) | -                |       
| Normal sMg (0.7–1.2 mmol/L) | 33 (0.7–1.1) | 13 (0.7–1.0)  | 20 (0.72–1.1)    | 0.02  
| High sMg (>1.25 mmol/L) | 17 (1.1–1.45) | 8 (1.1–1.37)  | 10 (1.14–1.45)   | 0.05  
| Osteoporosis (OP)  |             |               |                   |       
| With OP            | n=25       | n=17          | n=8               |       
| Without OP         | n=37       | n=17          | n=20              |       

Discussion and Conclusion

Mg imbalance has been neglected in disorders of bone mineral metabolism of patients with CKD [1,3,7,8]. Our study may give an additional light for improvement of medical care in CKD patients, with and without diabetes. Low serum Mg levels may cause wrong increase of PTH and may further lead to bone diseases in CKD patients, especially with diabetes. For these patients, adequate Mg intake by diet or supplement may reduce the development of low turnover bone disease [2,8,12,13]. Oppositely, the inhibitory effect of a high sMg on PTH secretion may be offset by the stimulation produced through low serum Ca in moderate-severe CKD patients, who are not receiving dialysis [5,7,9]. These patients must maintain a sCa within optimal range and avoid consuming excess Mg and, to reduce the risk of low-turnover bone diseases [7,13–15]. A routine monitoring of sMg, and balancing sCa and sMg are important in the assessment and management of bone mineral disorders in CKD patients with or without diabetes.

Disclosure statement

There is nothing to disclose.

References

1. Van Laecke S, Van Biesen W, Vanholder R (2012) Hypomagnesaemia, the kidney and the vessels. Nephrol Dial Transplant 27: 4003-4010.
2. João Matias P, Azevedo A, Laranjinha I, Navarro D, Mendes M, et al. (2014) Lower serum magnesium is associated with cardiovascular risk factors and mortality in haemodialysis patients. Blood Purif 38: 244-252.
3. Maier JA (2012) Endothelial cells and magnesium: implications in atherosclerosis. Clin Sci (Lond) 122: 397-407.
4. Yonova D (2009) Vascular calcification and metabolic acidosis in end stage renal disease. Hypokreatina Journal 13: 139-141.
5. Yonova D, Trendafilov I, Papazov V, Popov I (2012) Secondary hyperparathyroidism and oxidative stress in haemodialysis patients. Trakia Journal of Sciences Suppl 2: 60-62.
6. Tin A, Grams ME, Maruthur NM, Astor BC, Cooper D, et al. (2015) Results from the atherosclerosis risk in communities study suggest that low serum magnesium is associated with incident kidney disease. Kidney Int 87: 820-827.
7. Yonova D, Vazelov E, Trendafilov I, Stoïnova V, Nedeva M, et al. (2014) First impression of cardiovascular calcification treatment in hemodialysis patients with a new dialysis fluid containing sodium thiosulphate (STS). Int J Artif Organs 37: 299-307.
8. Alhosaini M, Leehey DJ (2015) Magnesium and dialysis: the neglected cation. Am J Kidney Dis 66: 523-531.
Yonova D (2020) The impact of Magnesium (Mg) on mineral metabolism in diabetic or non-diabetic patients with chronic kidney diseases (CKD)

9. Dousdampanis P, Trigka K, Fourtounas C (2014) Hypomagnesemia, chronic kidney disease and cardiovascular mortality: pronounced association but unproven causation. *Hemodial Int* 18: 730-739.

10. Kestenbaum B, Druke TB (2015) Disorders of calcium, phosphate, and magnesium metabolism. In: Johnson R, Feethally J, Fleige J, editors. Comprehensive Clinical Nephrology. ed 5. Philadelphia: 124-142.

11. Yonova D, Papazov V, Antov G (2005) Secondary HPT and oxidative stress in HD patients. Abstract book. 4th Annual Conference Prevention in Renal Disease, Toronto, Canada.

12. Abedinov F, Krastev P, Petrov I, Iliev R, Tsvetanova K (2018) Risk factors for prolonged length of stay in the ICU following cardiac surgery. *JISR* 7: 67-71.

13. Van de Wal-Vischer ER, Kooman JP, van der Sande FM (2018) Magnesium in chronic kidney disease: should we care? *Blood Purif* 45: 173-178.

14. Abedinov F, Bakalova N, Krastev Pl, Petrov I, Marinova R, et al. (2019) Survival and quality of life of patients with a prolonged stay in the intensive care unit after cardiac surgeries – remote results. *Copei Renal Acad Bulg Sci* 72: 1130-1136.

15. Sakaguchi Y, Hamano T, Isaka Y (2018) Magnesium and progression of chronic kidney disease: benefits beyond cardiovascular protection? *ACKD* 25: 274-280.

Copyright: ©2020 Yonova D. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.